Business
Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma
Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. TURKU, FI / ACCESS Newswire / January 27, 2026 / Faron Pharmaceuticals ...
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting.","length":190,"tagName":"p"},{"type":"text","content":"TURKU, FI / ACCESS Newswire / January 27, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces a significant expansion to scope of clinical trials where bexmarilimab is investigated by supporting the BEXAR investigator-initiated trial (IIT). Faron continues to leverage its deep understanding of the Clever-1 pathway to address solid tumors. The BEXAR trial evaluates Faron's lead asset, bexmarilimab , in combination with standard-of-care doxorubicin for patients with metastatic soft-tissue sarcoma.","length":635,"tagName":"p"},{"type":"text","content":"The IIT is being sponsored by MEDSIR, a global leader in oncology research, and conducted in collaboration with the University Hospital Vall d'Hebron in Barcelona, Spain, one of Europe's leading cancer treatment and research centers.","length":241,"tagName":"p"},{"type":"text","content":""The launch of the BEXAR trial represents a major milestone in our clinical strategy, extending the potential reach of bexmarilimab to solid tumors," said Dr. Petri Bono, Chief Medical Officer of Faron. "Sarcomas exhibit some of the highest levels of Clever-1 expression seen in oncology. This provides a strong scientific rationale for combining our macrophage-targeting immunotherapy with standard chemotherapy. We are thrilled to provide bexmarilimab to world-class experts at University Hospital Vall d'Hebron and MEDSIR to investigate this novel approach."","length":585,"tagName":"p"},{"type":"text","content":"Soft-tissue sarcomas are aggressive tumors often characterized by an immunosuppressive tumor microenvironment (TME) dominated by macrophages, which contribute to poor patient outcomes. Expansion into this indication is driven by compelling data showing that Clever-1 expression in sarcomas is among the highest of all human tumor types.","length":336,"tagName":"p"},{"type":"text","content":"Dr. César Serrano, Sarcoma Faculty of the European Society of Medical Oncology , sarcoma-expert oncolog...